- Home
- AUTL
as 07-09-2025 10:31am EST
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 625.4M | IPO Year: | 2018 |
| Target Price: | $9.32 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $5.00 | Next Earning Date: | 08-07-2025 |
| Revenue: | $9,011,000 | Revenue Growth: | -14.16% |
| Revenue Growth (this year): | 461.76% | Revenue Growth (next year): | 112.66% |
Latest Autolus Therapeutics plc News
AUTL Breaking Stock News: Dive into AUTL Ticker-Specific Updates for Smart Investing
MT Newswires
14 days ago
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
Insider Monkey
15 days ago
Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10
MT Newswires
15 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Simply Wall St.
15 days ago
Ardelyx Leads The Pack Of 3 Promising Penny Stocks
MT Newswires
16 days ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
GuruFocus.com
19 days ago
Syncona Ltd (LSE:SYNC) Full Year 2025 Earnings Call Highlights: Navigating Market Challenges ...
MT Newswires
21 days ago
European Equities Traded in the US as American Depositary Receipts Edge Higher Wednesday
MT Newswires
22 days ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
Compare AUTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUTL Autolus Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.